Top Pharma Companies in India 2024

The below table shows the top pharma stocks in India based on the highest market capitalization.

When it comes to investment, we tend to look for stocks that will stay relevant and perform well for an extended period. Pharmaceutical companies are stocks whose markets will always be relevant.

So this article is an effort to bring out the top pharma companies in India that have performed well in the past and look promising in the future.

You may find the analyzed lists of various factors in the article below. Keep reading to get an idea about the share market’s best pharma stocks.

Content:

• Best Pharma Stocks – 1Y Return
• Top pharma stocks in India – 1M Return
• Best Pharma Stocks in India – Daily Volume
• Best Pharma Stocks – PE Ratio
• Introduction to The Best Healthcare Stocks in India

Best Pharma Stocks

The below table shows the best pharma stocks based on 1 Year return.

Top Pharma Stocks in India

The below list has been curated upon the 1 Month return among the top pharma stocks in India.

Looking for the Best Stocks in different sectors? Check out the following articles:

Best Pharma Stocks in India – Daily Volume

The table below shows the best pharma stocks in India based on the highest volume.

Learn more about dividends and dividend payouts by clicking here; also, find out about the top dividend-paying companies in general.

Expanding our list of top pharma companies in India, we have also made a list of debt-free pharma stocks.

Read ahead to know more about it.

Best Pharma Stocks – PE Ratio

The table below shows the best pharma stocks based on PE Ratio.

Here are some of the Best Stock Research Articles listed based on Top Sectors (Industries), Market Cap, and Fundamental Analysis Factors:

Introduction to The Best Healthcare Stocks in India

Best Pharma Stocks – 1Y Return

Jeena Sikho Lifecare Ltd

The Market Cap of Jeena Sikho Lifecare Ltd is Rs. 2,921.07 crores. The stock’s monthly return is 6.63%. Its one-year return is 353.12%. The stock is 10.92% away from its 52-week high.

Jeena Sikho Lifecare Limited is an India-based ayurvedic healthcare company developing health care products and services. It offers a range of ayurvedic products under brands like Shuddhi, which addresses various diseases, and Origine Naturspired, focused on beauty and wellness. Key products include Shuddhi Kit, Shuddhi 32 Herbs Tea, Shuddhi Addiction Free Kit, Shuddhi BP Package, Shuddhi Diabetes Care Package, and Shuddhi Divya Sanjeevani Anti-Viral. The Shuddhi Kit supports digestion, immunity, hormone balance, and detoxification. The company also offers free health checkup camps and yoga sessions to raise health awareness.

Bharat Parenterals Ltd

The Market Cap of Bharat Parenterals Ltd is Rs. 848.13 crores. The stock’s monthly return is -18.68%. Its one-year return is 282.66%. The stock is 32.22% away from its 52-week high.

Bharat Parenterals Limited is an India-based pharmaceutical company focused on manufacturing pharmaceutical formulations. The Company engages in research, development, manufacturing, marketing, sourcing, and distribution of various pharmaceutical products. Its product range includes B-lactam antibiotics, anti-retrovirals, cephalosporin antibiotics, antiprotozoals/anthelmintics, respiratory drugs, antiallergics/antihistamines/anticolds, skin infection agents, antibiotics, cardiovascular drugs, antidiabetics, antituberculosis drugs, antifungals, antimalarials, gastrointestinal drugs, anti-inflammatories/antipyretics/analgesics, supplements, central nervous system drugs, anesthetics, antivirals, steroids and hormones, uterine stimulants, and anticancer drugs.

Lactose (India) Ltd

The Market Cap of Lactose (India) Ltd is Rs. 176.56 crores. The stock’s monthly return is -2.61%. Its one-year return is 224.17%. The stock is 11.92% away from its 52-week high.

Lactose (India) Limited is a pharmaceutical company based in India, primarily engaged in the manufacturing and trading of pharmaceutical products. The Company specializes in producing lactose monohydrate and disaccharide lactulose. Its product range includes liquid and solid dosage forms, excipients, and active pharmaceutical ingredients. The Company manufactures dry granulated, film, and lacquer-coated tablets and produces pharma color coatings with an annual capacity of 180 metric tons. Additionally, it offers prebiotic galacto-oligosaccharides (GOS) for various applications, including dairy products, beverages, bakery items, and nutritional products. The manufacturing facility is located in Taluka Savli, Vadodara, Gujarat.

Top Pharma Stocks In India – 1M Return

Coral Laboratories Ltd

The Market Cap of Coral Laboratories Ltd is Rs. 186.83 crores. The stock’s monthly return is 37.51%. Its one-year return is 122.11%. The stock is 3.30% away from its 52-week high.

Coral Laboratories Limited is an India-based manufacturer and exporter of pharmaceutical products, focusing on pharmaceutical formulations. Operating through the Formulations segment, its product range includes non-sterile, sterile, nutraceutical, and OTC lifestyle products. The Company produces tablets, capsules, ointments, creams, liquid orals, b-lactam, topical preparations, eye/ear drops, nasal sprays, dry syrups, gels, lotions, injections, granules, suppositories, and more. Therapeutic areas covered include antibiotics, antifungals, gastrointestinal drugs, analgesics, antispasmodics, muscle relaxants, antiprotozoals, anti-cold, herbal medicine, antiseptics, antimalarials, cough suppressants, and mouthwash.

GlaxoSmithKline Pharmaceuticals Ltd

The Market Cap of GlaxoSmithKline Pharmaceuticals Ltd is Rs. 41,180.07 crores. The stock’s monthly return is 23.44%. Its one-year return is 87.91%. The stock is 6.23% away from its 52-week high.

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company involved in manufacturing, distributing, and trading pharmaceuticals. It operates in three product areas: vaccines, specialty, and general medicines. Its general medicines portfolio includes brands like Augmentin, Calpol, and Betnovate, covering anti-infectives, pain, dermatology, and vitamins. Vaccine brands include Shingrix and Infanrix Hexa. The specialty medicines segment focuses on respiratory diseases and HIV, with brands like Nucala and Trelegy Ellipta. The Company is also expanding into immunology and oncology.

Bacil Pharma Ltd

The Market Cap of Bacil Pharma Ltd is Rs. 12.38 crores. The stock’s monthly return is 19.71%. Its one-year return is 214.32%. The stock is 0.46% away from its 52-week high.

Bacil Pharma Ltd is an India-based pharmaceutical company engaged in the production and marketing of pharmaceutical products. The Company’s core operations involve the manufacturing of various pharmaceutical formulations. Bacil Pharma specializes in creating a wide range of dosage forms, including tablets, capsules, injectables, syrups, and ointments. The Company’s product portfolio encompasses therapeutic areas such as antibiotics, anti-inflammatory drugs, and gastrointestinal medications. Bacil Pharma is dedicated to providing high-quality and affordable healthcare solutions to meet the diverse needs of patients.

Best Healthcare Stocks – Highest Volume

Marksans Pharma Ltd.

The Market Cap of Marksans Pharma Ltd is Rs. 7,633.54 crores. The stock’s monthly return is -11.81%. Its one-year return is 67.76%. The stock is 27.27% away from its 52-week high.

Marksans Pharma Limited, based in India, focuses on the research, manufacture, marketing, and sale of pharmaceutical formulations. It produces products across various therapeutic areas, including pain management, cardiovascular, anti-diabetic, and gastrointestinal treatments. The company operates four manufacturing facilities in India, the UK, and the US. In Goa, it manufactures oral solid tablets, soft gelatin capsules, and hard capsules, along with non-sterile liquids, ointments, and powder products. It serves markets in the UK, West Africa, and the Middle East, covering over 7000 square meters in the US.

Piramal Pharma Ltd

The Market Cap of Piramal Pharma Ltd is Rs. 19,460.51 crores. The stock’s monthly return is 2.39%. Its one-year return is 69.77%. The stock is 11.43% away from its 52-week high.

Piramal Pharma Limited, an India-based company, offers a wide range of pharmaceutical products through a domestic and global distribution network. It operates approximately 17 global facilities and distributes to over 100 countries. Its subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization, and Piramal Critical Care (PCC), specializing in complex hospital generics. PPS provides development and manufacturing solutions, while PCC’s portfolio includes inhalation anesthetics, pain management therapies, and injectable anti-infectives. The company also has a consumer healthcare segment selling over-the-counter products.

Syncom Formulations (India) Ltd

The Market Cap of Syncom Formulations (India) Ltd is Rs. 1,212.60 crores. The stock’s monthly return is -15.25%. Its one-year return is 69.50%. The stock is 56.07% away from its 52-week high.

Syncom Formulations (India) Limited is an India-based pharmaceutical company involved in manufacturing and dealing in pharmaceutical drugs and formulations, as well as trading commodities and renting properties. It produces a variety of pharmaceutical formulations in forms like tablets, capsules, oral liquids, liquid vials, ampoule injections, dry powder injections, ophthalmic preparations, dry syrups, suspensions, ointments, creams, gels, ORS, and jelly. Its domestic product divisions include Cratus Life Care, Cratus Evolve, and Cratus Right Nutrition, offering products like Ciprofloxacin and Ceftriaxone injections.

Best Healthcare Stocks – PE Ratio

IND Swift Laboratories Ltd

The Market Cap of IND Swift Laboratories Ltd is Rs. 625.43 crores. The stock’s monthly return is -15.69%. Its one-year return is 43.71%. The stock is 32.11% away from its 52-week high.

Ind-Swift Laboratories Limited is an India-based company specializing in the manufacturing of intermediates and formulations. The company’s products include advanced intermediates and active pharmaceutical ingredients (APIs) for both generic and innovative domains. It offers reference standards and impurities for over 25 APIs under various pharmacopeias, including BP and EP. All impurities come with comprehensive documentation, including a Certificate of Analysis and MSDS. The company’s research center, spanning 40,000 square feet, focuses on developing process technology for APIs across different therapeutic categories.

Desh Rakshak Aushdhalaya Ltd

The Market Cap of Desh Rakshak Aushdhalaya Ltd is Rs. 3.24 crores. The stock’s monthly return is 0.00%. Its one-year return is 21.30%. The stock is 0.00% away from its 52-week high.

Desh Rakshak Aushdhalaya Ltd is an India-based pharmaceutical company engaged in the production and distribution of a wide range of pharmaceutical products. The Company focuses on manufacturing ayurvedic medicines and herbal formulations. Desh Rakshak Aushdhalaya offers a variety of products aimed at promoting health and wellness, including herbal tonics, dietary supplements, and traditional remedies. The Company is committed to leveraging the power of natural ingredients to provide effective and safe healthcare solutions to its customers.

Ind Swift Ltd

The Market Cap of Ind Swift Ltd is Rs. 118.62 crores. The stock’s monthly return is -12.94%. Its one-year return is 132.04%. The stock is 48.57% away from its 52-week high.

Ind Swift Limited is an India-based pharmaceutical manufacturing and marketing company operating in both domestic and export markets. The Company is engaged in finished goods dosage, active pharmaceutical ingredients (APIs), and herbal products. It also produces hand sanitizers, face masks, and PPE kits. Operating through divisions like Noble, Nova, and Generic, it offers products like Zoxiclav and Glypar. The Company provides COVID-19 products, including masks and hand sanitizers, and has launched Stevia and Hangover products. It has five manufacturing plants in India.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.